Meta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin

被引:149
|
作者
Bartolucci, Alfred A. [1 ]
Tendera, Michal [2 ]
Howard, George [1 ]
机构
[1] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA
[2] Med Univ Silesia, Div Cardiol 3, Katowice, Poland
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 107卷 / 12期
关键词
RANDOMIZED CONTROLLED-TRIAL; PUBLICATION BIAS; GRAPHICAL TEST; DISEASE;
D O I
10.1016/j.amjcard.2011.02.325
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several meta-analyses have focused on determination of the effectiveness of aspirin (acetylsalicylic acid) in primary prevention of cardiovascular (CV) events. Despite these data, the role of aspirin in primary prevention continues to be investigated. Nine randomized trials have evaluated the benefits of aspirin for the primary prevention of CV events: the British Doctors' Trial (BMD), the Physicians' Health Study (PHS), the Thrombosis Prevention Trial (TPT), the Hypertension Optimal Treatment (HOT) study, the Primary Prevention Project (PPP), the Women's Health Study (WHS), the Aspirin for Asymptomatic Atherosclerosis Trial (AAAT), the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial, and the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial. The combined sample consists of about 90,000 subjects divided approximately evenly between those taking aspirin and subjects not taking aspirin or taking placebo. A meta-analysis of these 9 trials assessed 6 CV end points: total coronary heart disease, nonfatal myocardial infarction (MI), total CV events, stroke, CV mortality, and all-cause mortality. No covariate adjustment was performed, and appropriate tests for treatment effect, heterogeneity, and study size bias were applied. The meta-analysis suggested superiority of aspirin for total CV events and nonfatal MI, (p <0.05 for each), with nonsignificant results for decreased risk for stroke, CV mortality, and all-cause mortality. There was no evidence of a statistical bias (p >0.05). In conclusion, aspirin decreased the risk for CV events and nonfatal MI in this large sample. Thus, primary prevention with aspirin decreased the risk for total CV events and nonfatal MI, but there were no significant differences in the incidences of stroke, CV mortality, all-cause mortality and total coronary heart disease. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1796-1801)
引用
收藏
页码:1796 / 1801
页数:6
相关论文
共 50 条
  • [1] Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin
    Bartolucci, Alfred A.
    Howard, George
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (06): : 746 - 750
  • [2] Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin (vol 107, pg 1796, 2011)
    Bartolucci
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (04): : 615 - 615
  • [3] ASPIRIN FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS: AN UPDATED META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
    Shah, Rahman
    Rawal, Aranyak
    Najib, Khalid
    Khan, Babar
    Hesterberg, Kirstin
    Rashid, Abdul
    Latham, Samuel B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1782 - 1782
  • [4] Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events Reply
    Zheng, Sean L.
    Roddick, Alistair J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (22): : 2244 - 2245
  • [5] Aspirin for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
    De Berardis, Giorgia
    Sacco, Michele
    Graziano, Giusi
    Pellegrini, Fabio
    Nicolucci, Antonio
    DIABETES, 2009, 58 : A24 - A24
  • [6] Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis of randomized controlled trials
    Berwanger, Otavio
    Oliveira, Joao Bosco
    Suzumura, Erica
    Buhler, Anna M.
    Oliveira, Dinaldo
    Marx, Carlos B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A365 - A365
  • [8] Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
    De Berardis, Giorgia
    Sacco, Michele
    Strippoli, Giovanni F. M.
    Pellegrini, Fabio
    Graziano, Giusi
    Tognoni, Gianni
    Nicolucci, Antonio
    BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 : 1238
  • [9] Trials of Primary Prevention of Cardiovascular Events Using Aspirin
    Kappagoda, C. Tissa
    Amsterdam, Ezra A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (08): : 1198 - 1200
  • [10] Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
    Zhang, Chunyu
    Sun, Aijun
    Zhang, Peng
    Wu, Chaoneng
    Zhang, Shuning
    Fu, Mingqiang
    Wang, Keqiang
    Zou, Yunzeng
    Ge, Junbo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (02) : 211 - 218